title: [Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer].
abstract: The acquisition of a resistance EGFR mutation in exon 20 (T790M) occurs in half of the cases of secondary resistance to EGFR tyrosine kinase inhibitors (TKI), given in first-line treatment in advanced EGFR-mutated non-small cell lung cancers (NSCLC). Osimertinib (AZD9291, Tagrisso®) is a third-generation, irreversible EGFR TKI, active in case of T790M mutation. A large phase I trial showed the efficacy of osimertinib after failure of first-generation EGFR TKI (erlotinib, gefitinib), with response rate at 51% and up to 61% in case of T790M mutation. Progression-free survival was 9.6 months in case of T790M. Toxicity profile was acceptable, with mainly digestive (diarrhea) and skin (rash) side effects. Preliminary data from a phase II trial confirmed these efficacy and safety data. Screening of T790M mutation at the time of progression with TKI can be performed in circulating tumor DNA in plasma, with good diagnostic performances.
authors.affiliation: AP-HP, hôpital Ambroise-Paré, service de pneumologie et oncologie thoracique, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France; Université Paris-Saclay, UVSQ, laboratoire EA4340, biomarqueurs en cancérologie et onco-hématologie, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Giroux Leprieur
authors.affiliation: CHU de Lille, hôpital Calmette, service de pneumologie et oncologie thoracique, boulevard du Pr-Jules-Leclercq, 59000 Lille, France; Institut de biologie de Lille, UMR8161, 1, rue du Pr-Calmette, BP 245, 59019 Lille cedex, France.
authors.forename: Alexis B
authors.initials: AB
authors.lastname: Cortot
authors.affiliation: AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75020 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.affiliation: AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75020 Paris, France; Sorbonne universités, UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France. Electronic address: marie.wislez@aphp.fr.
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
mesh_terms: D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009154:Mutation; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles; D011743:Pyrimidines
chemical_list: D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D010879:Piperazines; D047428:Protein Kinase Inhibitors; C000596361:osimertinib; D007211:Indoles; D011743:Pyrimidines
keywords: ADN tumoral circulant; AZD9291; Cancer bronchique non à petites cellules; Circulating tumor DNA; EGFR; Non-small cell lung cancer; Osimertinib; T790M